October 30, 2019Open Access
View Full PaperGilteritinib or Chemotherapy for Relapsed or Refractory FLT3 -Mutated AML
Key Points
Key points are not available for this paper at this time.
Abstract
Gilteritinib resulted in significantly longer survival and higher percentages of patients with remission than salvage chemotherapy among patients with relapsed or refractory FLT3-mutated AML. (Funded by Astellas Pharma; ADMIRAL ClinicalTrials.gov number, NCT02421939.).